Treatment of focal spasticity with botulinum toxin: effect on the 'positive support reaction'.
Richardson
D
D
National Hospital for Neurology and Neurosurgery, London, UK. D.Richardson@ion.ucl.ac.uk
Greenwood
R
R
Sheean
G
G
Thompson
A
A
Edwards
S
S
D000293:Adolescent; D000328:Adult; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage / Q000627:therapeutic use*; D004576:Electromyography; D005260:Female; D005534:Foot Diseases / Q000503:physiopathology / Q000628:therapy*; D005684:Gait / Q000502:physiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009119:Muscle Contraction / Q000502:physiology; D009128:Muscle Spasticity / Q000503:physiopathology / Q000628:therapy*; D009465:Neuromuscular Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D010291:Paresis / Q000503:physiopathology; D011187:Posture / Q000502:physiology; D011782:Quadriplegia / Q000503:physiopathology; D016138:Walking / Q000502:physiology; D016474:Weight-Bearing / Q000502:physiology
D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A